At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Drug-eluting beads loaded with doxorubicin hydrochloridedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Patients With Hepatocellular Carcinoma Using Drug-Eluting Bead Embolization
In Brief
A clinical study evaluating Drug-eluting beads loaded with doxorubicin hydrochloride for Liver Cancer. Completed, enrolled 20 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: This clinical trial is studying how well chemoembolization using doxorubicin works in treating patients with liver cancer that cannot be removed by surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedFeb 2006
Primary CompletionApr 2011
TodayJul 2026
First PostedFeb 17, 2006
Enrollment StartNov 1, 2005
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 20.4 years ago
Interventions
Drug-eluting beads loaded with doxorubicin hydrochloridedevice
Doxorubicin eluting beads